Ind-Swift LaboratoriesNSE:INDSWFTLAB -1.38%48 Days Payable is 216.52 as of Mar. 2026, which is 130% above its 10-year median of 94.10. GuruFocus rates NSE:INDSWFTLAB with a GF Score™ of 48/100 and a GF Value™ of ₹37.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 921 Drug Manufacturers companies, Ind-Swift Laboratories ranks better than 86.86% on this metric.
The historical rank and industry rank for Ind-Swift Laboratories's Days Payable or its related term are showing as below:
NSE:INDSWFTLAB'
s Days Payable Range Over the Past 10 Years
Min: 89.38 Med: 94.1 Max: 255.5
Current: 217.79
During the past 13 years, Ind-Swift Laboratories's highest Days Payable was 255.50. The lowest was 89.38. And the median was 94.10.
NSE:INDSWFTLAB's Days Payable is ranked better than 86.86% of 921
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs NSE:INDSWFTLAB: 217.79
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDSWFTLAB vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ind-Swift Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Ind-Swift Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Ind-Swift Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ind-Swift Laboratories (NSE:INDSWFTLAB) has a Days Payable of 216.52 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ind-Swift Laboratories and its competitors. This is 130% above median its historical median of 94.10. Over the past decade, Ind-Swift Laboratories' Days Payable has ranged from 89.38 to 255.50. According to the industry distribution chart, Ind-Swift Laboratories ranks #121 out of 921 companies in the Drug Manufacturers industry, placing it in the top 13.1%.
Is Ind-Swift Laboratories' Days Payable too high?
Ind-Swift Laboratories' current Days Payable of 216.52 is 130% above median its 10-year median of 94.10. Over the past 10 years, this metric has ranged from a low of 89.38 to a high of 255.50. The Drug Manufacturers industry median Days Payable is 90.69. Ind-Swift Laboratories' value of 216.52 is 138.7% above this industry median. Based on the distribution chart, Ind-Swift Laboratories ranks #121 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ind-Swift Laboratories has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ind-Swift Laboratories' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ind-Swift Laboratories ranks #121 out of 921 companies for Days Payable. This places Ind-Swift Laboratories in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.69. Ind-Swift Laboratories' value of 216.52 is 138.7% above this benchmark. Historically, Ind-Swift Laboratories' own Days Payable has ranged from 89.38 to 255.50 over the past decade. While the company's 10-year median is 94.10 vs. the industry median of 90.69, Ind-Swift Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ind-Swift Laboratories's current Days Payable of 216.52 is 138.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ind-Swift Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ind-Swift Laboratories's current Days Payable is 216.52, which is 130% above median its own 10-year median of 94.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ind-Swift Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ind-Swift Laboratories (NSE:INDSWFTLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹37.04, compared to a current price of ₹200.73 — trading 441.9% above its estimated fair value. The current Days Payable is 216.52, which is 130% above median its 10-year median of 94.10 and 138.7% above the Drug Manufacturers industry median of 90.69. Ind-Swift Laboratories' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ind-Swift Laboratories (NSE:INDSWFTLAB), the current Days Payable is 216.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ind-Swift Laboratories (NSE:INDSWFTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued.
The current stock price of ₹200.73 is trading 441.9% above its estimated GF Value™ of ₹37.04.
GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:INDSWFTLAB:
Days Payable: 216.52 (130% above median its 10-year median of 94.10)
GF Value™: ₹37.04 vs. price of ₹200.73 (441.9% above fair value)
Industry Position: 138.7% above the Drug Manufacturers median (#121 of 921)
No single metric tells the full story. See the NSE:INDSWFTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
48GF Score
Get the complete analysis for NSE:INDSWFTLAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDSWFTLAB has been successfully added to your 
